Table of Contents 2
List of Tables 7
List of Figures 7
Novartis AG Spshot 8
Novartis AG Overview 8
Key Information 8
Key Facts 8
Novartis AG - Research and Development Overview 9
Key Therapeutic Areas 9
Novartis AG - Pipeline Review 28
Pipeline Products by Stage of Development 28
Pipeline Products - Monotherapy 29
Pipeline Products - Combition Treatment Modalities 30
Pipeline Products - Partnered Products 31
Pipeline Products - Out-Licensed Products 34
Novartis AG - Pipeline Products Glance 36
Novartis AG - Late Stage Pipeline Products 36
Novartis AG - Clinical Stage Pipeline Products 40
Novartis AG - Early Stage Pipeline Products 49
Novartis AG - Drug Profiles 52
ceritinib 52
dabrafenib mesylate + trametinib dimethyl sulfoxide 55
eltrombopag olamine 57
everolimus 60
serelaxin 66
trametinib dimethyl sulfoxide 69
zoledronic acid 72
imatinib mesylate 74
panobinostat 77
pazopanib hydrochloride 84
(glycopyrrolate + indacaterol maleate + mometasone fuorate) 89
(indacaterol maleate + mometasone furoate) 90
(sacubitril + valsartan) 92
alpelisib 95
bimagrumab 97
buparlisib hydrochloride 99
cakinumab 103
dabrafenib mesylate 106
fevipiprant 109
fingolimod hydrochloride 111
midostaurin 114
nilotinib 116
ofatumumab 120
osilodrostat phosphate 125
oxytocin 127
pasireotide 129
pasireotide ER 132
ranibizumab 134
ribociclib 138
secukinumab 141
siponimod 147
CDZ-173 149
clofazimine 150
CNP-520 151
(dectrekumab + VAK-694) 152
afuresertib hydrochloride 153
aldesleukin 156
BHQ-880 158
BVS-857 160
capmatinib 161
CFZ-533 164
cipargamin 166
CJM-112 167
dectrekumab 168
EGF-816 170
elgemtumab 171
EMA-401 173
FCR-001 175
GSK-2285921 177
HSC-835 179
iloperidone 180
infigratinib 182
KAF-156 183
KRP-203 184
LCL-161 186
LFX-453 188
LHW-090 189
ligelizumab 190
LJN-452 192
LMI-070 193
mavoglurant 194
MCS-110 196
octreotide acetate long acting 197
pradigastat sodium 199
ruxolitinib phosphate 200
selurampanel 205
sonidegib phosphate 206
tesidolumab 210
tisagenlecleucel-T 212
trametinib dimethyl sulfoxide + uprosertib 215
uprosertib 217
VAY-736 218
BZF-961 220
CGF-166 221
CSJ-137 223
CSJ-148 224
FGF-401 225
HDM-201 226
LAG-525 227
lapatinib ditosylate 228
MGB-453 232
PDR-001 233
PIM-447 234
RAF-265 235
sotrastaurin acetate 236
ABL-001 238
AV-380 239
Cellular Immunotherapy to Target c-Met for Oncology 240
Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia 241
Cellular Immunotherapy to Target EGFR for Glioblastoma 242
CGM-097 243
CLR-325 244
huCART19 245
IDH-305 246
IMP-701 247
LEQ-506 248
LGK-974 249
LML-134 250
L-043 251
LXH-254 252
LXS-196 253
MesoCART 254
NOV-10 255
NOV-11 256
NOV-7 257
NOV-8 258
NOV-9 259
octreotide acetate LAR 260
PBF-509 261
PCA-062 263
QCC-374 264
CART-123 265
Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma 266
Antibody to Inhibit PD-L1 for Oncology 267
AUSRM-057 268
BLZ-945 269
BQS-481 271
BVB-808 272
Cellular Immunotherapy Program for Oncology 273
Cellular Immunotherapy to Target GD2 for Neuroblastoma 274
CHZ-868 275
cosyntropin ER 276
ESK-1 277
GNFPf-5069 278
Kartogenin 279
KR-22809 280
LCZ-960 281
LGB-321 282
LKZ-145 283
LQN-725 284
Monoclol Antibody to Inhibit CXCR2 for Respiratory Diseases 285
NIBR-0213 286
NITD-349 287
NITD-916 288
NVPQBE-170 289
NVPTNKS-656 290
OXB-302 291
RP-6503 292
Small Molecule to Agonize GPR119 for Type 2 Diabetes 293
Small Molecule to Agonize GPR39 for Type 2 Diabetes 294
Small Molecule to Agonize Nurr1 for Multiple Sclerosis 295
Small Molecule to Inhibit LRRK2 for Parkinson’s Disease 296
Small Molecule to Inhibit OX2R for Insomnia 297
Small Molecules to Antagonize VEGFR2 for Solid Tumors 298
Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis 299
Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes 300
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer 301
Small Molecules to Inhibit Pan-RAF Kise for Oncology 302
Small Molecules to Inhibit Renin for Hypertension 303
XOMA-089 304
ESBA-903 SR 305
LJH-685 306
Monoclol Antibodies to Inhibit CTLA4 and PD-1 for Oncology 307
Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD 308
Small Molecules for Tuberculosis 309
Small Molecules for Undisclosed Indication 310
Small Molecules to Antagonize NR2B for Depression 311
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections 312
Small Molecules to Inhibit CFTR for Secretory Diarrhea 313
Small Molecules to Inhibit FPPS for Soft Tissue Cancer 314
Small Molecules to Inhibit PfATP4 for Malaria 315
Small Molecules to Inhibit PI4KIIIbeta for HCV 316
Novartis AG - Pipeline Alysis 317
Novartis AG - Pipeline Products by Target 317
Novartis AG - Pipeline Products by Route of Administration 330
Novartis AG - Pipeline Products by Molecule Type 331
Novartis AG - Pipeline Products by Mechanism of Action 332
Novartis AG - Recent Pipeline Updates 342
Novartis AG - Dormant Projects 436
Novartis AG - Discontinued Pipeline Products 443
Novartis AG - Discontinued Pipeline Products 443
Discontinued Pipeline Product Profiles 445
Novartis AG - Company Statement 457
Novartis AG - Locations And Subsidiaries 458
Head Office 458
Other Locations & Subsidiaries 458
Appendix 475
Methodology 475
Coverage 475
Secondary Research 475
Primary Research 475
Expert Panel Validation 475
Contact Us 475
Disclaimer 476